"Yao Jiasu" announced the completion of a multi-million-yuan angel round of financing, with Light Source Capital serving as the exclusive financial advisor.
Hangzhou Yaojiasu Medical Isotope Technology Co., Ltd. (hereinafter referred to as "Yaojiasu"), a hard - tech enterprise dedicated to breaking through the supply bottleneck of GMP - grade medical isotopes, officially announced today that it has completed an angel - round financing of tens of millions of RMB. This round of financing was jointly participated in by the Innovation Institute of Zhejiang University, Bangming Capital, and industrial player Wuzhou Medical. Light Source Capital served as the exclusive financial advisor. The financing funds will be mainly used for expanding the core team, advancing technological R & D, and promoting the commercialization process of key products such as the α - nuclide Ac - 225.
Nuclides, also known as radioactive isotopes, demonstrate unique advantages in disease diagnosis and treatment due to their precise radioactive properties, with broad clinical application prospects. Among numerous medical nuclides, α - nuclides are regarded as an important direction for the next - generation nuclear medicine treatment because of their excellent targeted killing ability, high safety, and low toxic and side effects. Take Ac - 225 (actinium - 225) as an example. It has a moderate half - life, which facilitates production, transportation, and stable binding with targeted molecules. In the field of tumor treatment, Ac - 225 shows outstanding application potential, especially having an excellent targeted killing effect on widely metastasized micrometastases.
Yaojiasu is committed to breaking through the supply bottleneck of medical isotopes, aiming to build a high - performance, high - efficiency, and replicable domestic nuclide technology engineering system. The company is building an integrated platform of "high - energy and high - current electron accelerator + high - power target station system + GMP - grade separation and purification process" around the medical radioactive isotope production technology driven by electron accelerators to promote the large - scale preparation and engineering implementation of actinides and diagnosis - treatment integrated nuclides. Based on the self - designed high - power electron linear accelerator system, the company has constructed a precision target station with high - power load capacity, a rapid heat - exchange structure, and a short - range and efficient cooling path. Coupled with a multi - stage separation and purification process, it can achieve stable production and strict quality control of key nuclides such as Ac - 225, Cu - 67, Sc - 47, and Mo - 99. The entire system supports rapid target replacement, remote maintenance, and modular expansion capabilities, suitable for continuous operation scenarios, laying a solid hardware foundation for the large - scale mass production of nuclides such as Ac - 225.
Yaojiasu's R & D team brings together experts in accelerator physics, electro - vacuum, and nuclear chemical separation from institutions such as the Chinese Academy of Sciences, the University of Science and Technology of China, and Harbin Institute of Technology. They have the full - chain technical capabilities from accelerator design and manufacturing, optimization of nuclear reaction paths to process scaling - up and industrialization of nuclide separation processes.
After the completion of this round of financing, Yaojiasu will further accelerate the construction of its production lines and technological iteration, promote the commercial production and delivery of core nuclides such as Ac - 225, and contribute to the high - quality and independent development of China's nuclear medicine diagnosis and treatment industry.
Gu Shengdong, co - founder and CEO of Yaojiasu, said: "We are very grateful for the support of all shareholders and Light Source Capital, which gives us more strength to do things well. The nuclear medicine industry is developing rapidly, and medical isotopes are crucial for cancer diagnosis and treatment. Yaojiasu has solid technical accumulation and team capabilities. We will go all out to accelerate R & D and industrialization, ensure stable production as soon as possible, and bring truly usable results to patients."
The Innovation Institute of Zhejiang University said: "The excellent clinical data of innovative nuclear medicines have brought explosive growth to the entire nuclear medicine industry. Among them, nuclide production is a crucial part of the entire industrial chain. The Yaojiasu team has rich experience in accelerator manufacturing, debugging, and nuclide separation and purification. They produce innovative nuclides through high - current electron accelerators to solve the current global shortage of nuclides. We look forward to the company's early completion of the commercial production of nuclides to benefit a large number of patients."
Bangming Capital said: "Bangming has always adhered to the concepts of 'long - termism' and 'value discovery and creation'. We are very optimistic about the development prospects of α - nuclide radioactive drugs in the field of tumor treatment. The Yaojiasu team has years of technical accumulation in accelerator design and manufacturing, optimization of nuclear reaction paths, process scaling - up and industrialization of nuclide separation. Their self - developed high - energy and high - current electron accelerator is expected to achieve the commercial mass production of α - nuclides, solving the dual bottlenecks of technology and production capacity that China has long relied on imports for. Bangming is honored to participate in a science and technology innovation enterprise with growth potential like Yaojiasu and is willing to continuously support the enterprise's rapid development and jointly build the cause of science and technology innovation."
Wuzhou Medical said: "Although Ac - 225 performs outstandingly in clinical applications, its production process is complex, and the global supply is extremely limited, severely restricting clinical applications. Yaojiasu can overcome the core technology of Ac - 225 mass production, which is expected to solve the problem of Ac - 225 supply shortage. This is not only a major breakthrough in the nuclear medicine industry but also brings hope to a large number of cancer patients."
Hong Lei, the head of the medical department and managing director of Light Source Capital, said: "Currently, the global nuclear medicine industry is in a period of vigorous development, and its clinical value has been widely recognized. Innovation and breakthroughs in this field highly depend on the stable supply of isotopes, which are the underlying foundation. The production of isotopes, especially new nuclides such as Ac - 225, has become a key restrictive factor for the industry's development. For a long time, China has highly relied on imports for high - value new nuclides, restricting the independent development of the industry. Yaojiasu, with its integrated technology platform, directly addresses the pain points of the'supply - chain bottleneck' and is expected to break this pattern of external dependence. We are very optimistic about the company's technical path and team execution ability. In the future, Light Source will continue to provide in - depth capital and strategic support to help the company seize historical opportunities and grow into a core force leading the development of China's medical nuclide industry."
About the Innovation Institute of Zhejiang University
The Innovation Technology Research Institute Co., Ltd. of Zhejiang University is jointly established by the holding group of Zhejiang University on behalf of Zhejiang University, with the controlling stake funded by the State - owned Assets Supervision and Administration Commission of Zhejiang Province, and jointly formed by state - owned enterprises in Zhejiang Province and Hangzhou, as well as many well - known listed companies, private industrial leaders, and financial investment groups. The company has long been engaged in the work of scientific and technological achievement transformation, incubation, and industrialization. It is committed to the transformation, incubation, and investment operation of scientific and technological innovation projects, cultivating the ecological environment of emerging industries, and providing new - quality services for regional economic construction and development.
About Bangming Capital
Bangming Capital was established in 2010. It is a professional venture capital institution that has long adhered to the value investment concept and invested in "technology + entrepreneurship" - type enterprises. Currently, it is the vice - president unit of the Shanghai Venture Capital Industry Association. Since its establishment, Bangming Capital has always focused on key technologies and scientific and technological innovations in three major fields: integrated circuits and the new - generation electronic information, innovative medical biology, and new materials and new energy. Upholding the spirit of "long - termism" and the concept of value discovery/value creation, we adhere to growing and building the cause of science and technology innovation together with China's most promising science and technology innovation enterprises and entrepreneurs.
About Wuzhou Medical
Hangzhou Wuzhou Medical Equipment Co., Ltd. was established on January 22, 2003. At the beginning of its establishment, the company established the mission of promoting early diagnosis and treatment and making life better. It is committed to providing early diagnosis and treatment products for thousands of customers and early diagnosis and treatment services for hundreds of millions of people. Currently, the company has four branches across the country, and its services cover medical institutions in four regions: Zhejiang, Shanxi, Gansu, and Tianjin, promoting relevant projects such as the Zhonghe Haidewei breath test, the Hunan Youli prostate small extracellular protein (PSEP) detection kit, and the early - stage diabetes risk screening by the Chinese Academy of Sciences.